No Data
Guangxi Wuzhou Zhongheng Group (600252.SH) subsidiary Chongqing Lummy Pharmaceutical participated in the tenth batch of national Pharmaceutical centralized procurement is expected to be selected.
Guangxi Wuzhou Zhongheng Group (600252.SH) announced that its holding subsidiary Chongqing Lummy Pharmaceutical Co., Ltd. (referred to as "...")
Chongqing Lummy Pharmaceutical (300006.SZ): Nimodipine injection is expected to be selected for centralized procurement.
On December 13, Gelonghui reported that Chongqing Lummy Pharmaceutical (300006.SZ) announced its participation in the bidding process for the tenth batch of national centralized pharmaceutical procurement organized by the National Joint Procurement Office (referred to as the 'Joint Procurement Office'). According to the 'Public Announcement of the Proposed Results for National Centralized Pharmaceutical Procurement' released by the Joint Procurement Office, the company's product, Nimodipine Injection, is proposed to be selected for this centralized procurement, with a proposed selection price of 3.90 yuan per bottle.
Chongqing Lummy Pharmaceutical (300006.SZ): The controlling shareholder plans to transfer part of the company's shares through an agreement and is publicly soliciting transferees.
Gelonghui reported on December 12 that Chongqing Lummy Pharmaceutical (300006.SZ) announced that its controlling shareholder Guangxi Wuzhou Zhongheng Group Co., Ltd. (hereinafter referred to as "Zhongheng Group") intends to transfer its 247,426,064 shares of unrestricted circulating A-shares through a public solicitation of transferees, accounting for 23.43% of the company's total share capital. The transfer price will not be less than the arithmetic average of the daily weighted average price of the 30 trading days prior to the announcement, which is 4.42 yuan/share. The implementation of this public solicitation transfer may result in changes to the company's controlling shareholder and actual controller.
Guangxi Wuzhou Zhongheng Group (600252.SH): Plans to transfer shares of Chongqing Lummy Pharmaceutical and has obtained approval from the Guangxi State-owned Assets Supervision and Administration Commission.
On December 12, according to Gelonghui, Guangxi Wuzhou Zhongheng Group (600252.SH) announced that on December 12, 2024, the company received a notice from its controlling shareholder, Guangxi Investment Group Co., Ltd. The plan to publicly solicit transferees for transferring the company's 23.43% stake in Chongqing Lummy Pharmaceutical has been approved by the State-owned Assets Supervision and Administration Commission of the People's Government of Guangxi Zhuang Autonomous Region, and in principle, Guangxi Wuzhou Zhongheng Group has publicly solicited potential transferees for its 247,426,064 A-share shares in Chongqing Lummy Pharmaceutical.
Chongqing Lummy Pharmaceutical (300006.SZ): Nimodipine injection, Omeprazole magnesium enteric-coated tablets have been included in the medical insurance catalog.
chongqing lummy pharmaceutical (300006.SZ) released an announcement, according to the National Medical Security Administration, Ministry of Human Resources and Social Security...
Lummy Pharmaceutical Gets Nod For Alanyl Glutamine Injection's Two Specifications; Shares Up 8%
Chongqing Lummy Pharmaceutical Co., Ltd.'s (SZSE:300006) Popularity With Investors Under Threat As Stock Sinks 28%
No Data
